TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratification. Key uncertainties include timing dependency—TREM2 agonism likely beneficial only in early-mid disease—and species differences in TREM2 signaling.
...
TREM2 loss-of-function variants impair microglial survival, clustering around amyloid plaques, and phagocytic clearance, creating a non-cell-autonomous amplification loop where dysfunctional microglia accelerate tau pathology. This hypothesis has the strongest human genetic support (R47H OR ~2-4 for AD risk) and active clinical validation through AL002c Phase II trials (TRAILBLAZER-ALZ2). The mechanism is druggable via agonism antibodies, with validated biomarker (sTREM2) for patient stratification. Key uncertainties include timing dependency—TREM2 agonism likely beneficial only in early-mid disease—and species differences in TREM2 signaling. The Skeptic's revised 0.78 confidence captures the modest effect size and bidirectional complexity, while Domain Expert assigns 0.82 reflecting the clinical validation trajectory.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["TREM2 Deficiency Microglial Lipid Sensing Loss"]
B["DAM Transition Failure Failed Amyloid Phagocytosis"]
C["Amyloid Plaque Accumulation"]
D["Plaque-Associated Neurite Dystrophy"]
E["Synaptic Loss Cognitive Decline"]
F["TREM2-Deficient Microglia as Drivers of Toxicity"]
A --> B
B --> C
C --> D
D --> E
A --> F
F --> C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations3 with PMIDValidation: 0%5 supporting / 3 opposing
✓For(5)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
5
1
MECH 2CLIN 5GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
TREM2 R47H and R62H variants confer AD risk in lar…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Legacy Pre-Pipeline Hypotheses: Neurodegeneration
Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.
IF AL002c (TREM2 agonism antibody) is administered to prodromal-mild AD patients (CDR 0.5-1.0) with elevated amyloid PET for ≥18 months THEN plasma p-tau181 concentration will increase significantly more slowly in the treatment arm compared to placebo (≥30% reduction in annualized rate).
pendingconf: 0.74
Expected outcome: ≥30% reduction in plasma p-tau181 annualized rate of change in AL002c-treated group vs. placebo in prodromal-mild AD
Falsified by: No statistically significant difference (p>0.05) in annualized plasma p-tau181 change between treatment and placebo arms after 18 months, regardless of amyloid burden reduction
Method: Phase II/III randomized double-blind placebo-controlled trial (TRAILBLAZER-ALZ2 or equivalent) enrolling prodromal-mild AD (CDR 0.5-1.0) with confirmed brain amyloid positivity, measuring plasma p-tau181 (Elecsys or Lumipulse assay) and CSF p-tau181 longitudinally at baseline, 6, 12, and 18 months
IF TREM2 agonism enhances microglial amyloid phagocytosis in early-mid AD THEN 18F-flutemetamol PET SUVR will decline significantly faster in the AL002c arm than placebo due to reduced plaque burden, with amyloid clearance detectable by 12 months.
pendingconf: 0.68
Expected outcome: Significantly greater reduction in cortical amyloid PET SUVR (≥0.05 units) in AL002c-treated early-mid AD patients vs. placebo after 12-18 months of treatment
Falsified by: Amyloid PET SUVR in treatment arm shows equal or greater accumulation compared to placebo (i.e., treatment fails to reduce or slows amyloid burden), indicating TREM2 agonism does not enhance phagocytic clearance in human AD brain
Method: Multicenter randomized controlled trial with amyloid PET imaging (18F-flutemetamol or 11C-PiB) at baseline and 12/18 months in early-mid AD cohort stratified by baseline sTREM2 levels, with quantitative partial volume-corrected SUVR analysis in predefined regions (prefrontal, lateral temporal, parietal cortex)